A First-In-Human, Phase 1 Study Evaluating Oral TACC3 PPI Inhibitor, AO-252, in Advanced Solid Tumors
Status:
Recruiting
Trial end date:
2027-01-27
Target enrollment:
Participant gender:
Summary
The purpose of this study is to assess the safety, tolerability and efficacy of the study
drug AO-252 and identify the best dose for use in future studies.